{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VHL+-+Von+Hippel-Lindau+Syndrome&page=2",
    "query": {
      "condition": "VHL - Von Hippel-Lindau Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VHL+-+Von+Hippel-Lindau+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:53:32.189Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03401788",
      "title": "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL - Von Hippel-Lindau Syndrome",
        "VHL Gene Mutation",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "VHL-Associated Renal Cell Carcinoma",
        "VHL-Associated Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-05-02",
      "completion_date": "2027-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 8,
      "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401788"
    },
    {
      "nct_id": "NCT03001349",
      "title": "68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Meningioma",
        "Metastatic Well Differentiated Neuroendocrine Neoplasm",
        "Multiple Endocrine Neoplasia Type 1",
        "Neuroendocrine Neoplasm",
        "Somatostatin Positive Neoplastic Cells Present",
        "Von Hippel-Lindau Syndrome"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-Edotreotide",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2017-05-16",
      "completion_date": "2021-02-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03001349"
    },
    {
      "nct_id": "NCT04924075",
      "title": "Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pheochromocytoma/Paraganglioma",
        "Pancreatic Neuroendocrine Tumor",
        "Von Hippel-Lindau Disease",
        "Advanced Gastrointestinal Stromal Tumor",
        "HIF-2α Mutated Cancers"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 322,
      "start_date": "2021-08-12",
      "completion_date": "2029-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924075"
    },
    {
      "nct_id": "NCT03050268",
      "title": "Familial Investigations of Childhood Cancer Predisposition",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Leukemia",
        "Adenomatous Polyposis",
        "Adrenocortical Carcinoma",
        "AML",
        "BAP1 Tumor Predisposition Syndrome",
        "Carney Complex",
        "Choroid Plexus Carcinoma",
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Diamond-Blackfan Anemia",
        "DICER1 Syndrome",
        "Dyskeratosis Congenita",
        "Emberger Syndrome",
        "Familial Acute Myeloid Leukemia",
        "Familial Adenomatous Polyposis",
        "Fanconi Anemia",
        "Familial Cancer",
        "Familial Wilms Tumor",
        "Familial Neuroblastoma",
        "GIST",
        "Hereditary Breast and Ovarian Cancer",
        "Hereditary Paraganglioma-Pheochromocytoma Syndrome",
        "Hodgkin Lymphoma",
        "Juvenile Polyposis",
        "Li-Fraumeni Syndrome",
        "Lynch Syndrome",
        "MDS",
        "Melanoma Syndrome",
        "Multiple Endocrine Neoplasia Type 1",
        "Multiple Endocrine Neoplasia Type 2",
        "Neuroblastoma",
        "Neurofibromatosis Type 1",
        "Neurofibromatosis Type II",
        "Nevoid Basal Cell Carcinoma Syndrome",
        "Non Hodgkin Lymphoma",
        "Noonan Syndrome and Other Rasopathy",
        "Overgrowth Syndromes",
        "Pancreatic Cancer",
        "Peutz-Jeghers Syndrome",
        "Pheochromocytoma/Paraganglioma",
        "PTEN Hamartoma Tumor Syndrome",
        "Retinoblastoma",
        "Rhabdoid Tumor Predisposition Syndrome",
        "Rhabdomyosarcoma",
        "Rothmund-Thomson Syndrome",
        "Tuberous Sclerosis",
        "Von Hippel-Lindau Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1500,
      "start_date": "2017-04-06",
      "completion_date": "2037-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050268"
    },
    {
      "nct_id": "NCT07405164",
      "title": "Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Hippel-Lindau Disease",
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2026-03-23",
      "completion_date": "2034-01-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07405164"
    },
    {
      "nct_id": "NCT00001668",
      "title": "Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Deafness",
        "Kidney Diseases",
        "Kidney Neoplasms",
        "Neoplasms",
        "Retinal Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 75,
      "start_date": "1997-04",
      "completion_date": "2000-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001668"
    },
    {
      "nct_id": "NCT02108002",
      "title": "Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Hippel-Lindau Disease"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2014-04-05",
      "completion_date": "2018-09-12",
      "has_results": false,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02108002"
    },
    {
      "nct_id": "NCT03108066",
      "title": "MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL Gene Mutation",
        "VHL",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "Von Hippel",
        "Von Hippel-Lindau Disease",
        "Von Hippel's Disease",
        "Von Hippel-Lindau Syndrome, Modifiers of",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "MK-3795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-04-24",
      "completion_date": "2023-09-27",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108066"
    },
    {
      "nct_id": "NCT05955014",
      "title": "Data Collection Protocol for Patients With Von Hippel Lindau Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Hippel Lindau Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2023-08-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05955014"
    },
    {
      "nct_id": "NCT05737602",
      "title": "Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Von Hippel-Lindau Disease",
        "Genetic Disorder"
      ],
      "interventions": [
        {
          "name": "3RP-VHL",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-07-30",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-05-22T07:53:32.189Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737602"
    }
  ]
}